Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): A randomized comparison between two 7-day triple therapies and a 14- day dual therapy

American Journal of Gastroenterology

Volumn 93, Issue 7, 1998, Pages 1101-1107

  De Boer, Wink A ^a   Haeck, Peter W E ^b   Otten, Marten H ^b   Mulder, Chris J J ^b  

^a ST ANNA HOSPITAL   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; RANITIDINE BISMUTH CITRATE; TETRACYCLINE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; ENDOSCOPY; FEMALE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH BIOPSY; STOMACH ULCER;

ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PENICILLINS; RANITIDINE; STOMACH ULCER; TETRACYCLINE; TREATMENT OUTCOME;

EID: 0032455535     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(98)00218-4     Document Type: Article

References (52)

1. 1. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 33:984-91.
2. 2. NIH consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
3. 3. Soll AH. Consensus statement. Medical treatment of peptic ulcer disease. Practice guidelines. JAMA 1996;275:622-9.
4. 4. de Boer WA, Tytgat GNJ. 90% Cure; which anti-Helicobacter therapy can achieve this treatment goal. (Editorial). Am J Gastroenterol 1995; 90:1381-2.
5. 5. Neil GA. Do ulcers burn out or burn on? Managing duodenal ulcer diathesis in the Helicobacter pylori era. Am J Gastroenterol 1997;92: 387-92.
6. 6. Hopkins RJ, Girardi LS, Tumey EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996;110:1244-52.
7. 7. Carrere MO, Lamouliatte H, Ruszniewski P. Is Helicobacter pylori eradication a cost-effective treatment of duodenal ulcer disease? Pharmacoeconomics 1997;11:216-24.
8. 8. Wilhelmsen I. Quality of life and Helicobacter pylori eradication. Scand J Gastroenterol 1996;31(suppl 221):18-20.
9. 9. Chiba N, Rao BV, Rademaker JW, et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992;87:1716-27.
10. 10. Lambert, Midolo P. The actions of bismuth in the treatment of Helicobacter pylori. Aliment Pharmacol Ther 1997;11 (suppl 1):27-33.
11. 11. Lopez-Brea M, Sanchez I, Domingo D, et al. Synergism study of ranitidine bismuth citrate and metronidazole against metronidazole resistant Helicobacter pylori clinical isolates. Gastroenterology 1997; 112:A201.
12. 12. van der Hulst RWM, Keller JJ, Rauws EAJ, et al. Treatment of Helicobacter pylori infection in humans: A review of the world literature. Helicobacter 1996;1:6-19.
13. 13. de Boer WA, Driessen WMM, Jansz AR, et al. Effect of acid suppression on efficacy of treatment for Helicobacter pylori. Lancet 1995;345:817-20.
14. 14. de Boer WA, Driessen WMM, Jansz AR, et al. Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients. Eur J Gastroenterol Hepatol 1995;7:1189-94.
15. 15. Chiba N, Hunt RH. Bismuth, metronidazole and tetracycline and acid suppression in H. pylori eradication: A meta-analysis. Gut 1996; 39(suppl 2):A36-7.
16. 16. Mc Colm AA, Mc Laren A, Klinkert G, et al. Ranitidine bismuth citrate: A novel anti-ulcer agent with different physico-chemical characteristics and improved biological activity to a bismuth citrate-ranitidine admixture. Aliment Pharmacol Ther 1996;10:241-50.
17. 17. Pipkin GA, Mills JG, Kler L, et al. The safety of ranitidine bismuth citrate in controlled clinical studies. Pharmacoepidemiol Drug Safety 1996;5:399-407.
18. 18. Gudjonsson H, Bardhan KD, Hoie O, et al. High H. pylori eradication rate with a one week triple regimen containing ranitidine bismuth citrate. Gut 1997;41(suppl 1):A99.
19. 19. Axon ATR, Ireland A, Lancaster Smith MJ, et al. Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1997;11:81-7.
20. 20. Marchi S, Costa F, Di Matteo G, et al. Ranitidine bismuth citrate in co-prescription with clarithromycin 1 g/day or 1.5 g/day are equally effective in the eradication of Helicobacter pylori and healing of duodenal ulcers. Gastroenterology 1997;112:A210.
21. 21. Bardhan KD, Wurzer H, Marcelino M, et al. High cure rates with ranitidine bismuth citrate (pylorid) plus clarithromycin given twice daily. Gut 1996;39(suppl 2):A36.
22. 22. Kolkman JJ, Tan TG, Oudkerk Pool M, et al. Dual therapy with ranitidine bismuth citrate and clarithromycin is superior to omeprazole and amoxycillin in the cure of Helicobacter pylori infection. Gastroenterology 1997;112:A180.
23. 23. Pare P, Romaozinho J, Bardhan KD, et al. Ranitidine bismuth citrate is more effective than omeprazole in the eradication of H. pylori when co-prescribed with clarithromycin. Gastroenterology 1997;112:A251.
24. 24. Megraud F, Pichavant R, Palegry D, et al. Ranitidine bismuth citrate co-prescribed with clarithromycin is more effective in the eradication of Helicobacter pylori than omeprazole with clarithromycin. Gut 1997;41(suppl 1):A92.
25. 25. Sung JY, Leung WK, Ling TKW, et al. One-week RBC triple therapy versus PPI triple therapy for the treatment of H. pylori associated duodenal ulcers. Gut 1997;41(suppl 3):A51-2.
26. 26. Catalano F, Catanzaro R, Bentivegna C, et al. Helicobacter positive duodenal ulcer treated with omeprazole or ranitidine bismuth citrate triple therapy. Gut 1997;41(suppl 3):A213.
27. 27. Ravizza M, Dusio P, Giacobbe U, et al. Results of Helicobacter pylori eradication by three different one-week regimens. Gastroenterology 1998;114:A265.
28. 28. Laine L, Estrada R, Trujillo M, et al. Randomized comparison of ranitidine bismuth citrate based triple therapies for H. pylori. Gastroenterology 1997;112:A192.
29. 29. Savarino V, Mansi C, Mele MR, et al. Eradication of Helicobacter pylori using one-week therapy combining ranitidine bismuth citrate with two antibiotics. Gastroenterology 1997;112:A280.
30. 30. Williams M, Sercombe J, Pounder RE. Ranitidine bismuth citrate plus clarithromycin and tetracycline: A seven day Helicobacter pylori eradication regimen. Gastroenterology 1997;112:A330.
31. 31. Wyeth JW, Pounder RE, Duggan AE, et al. The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996;10:623-30.
32. 32. Spadaccini A, De Fanis C, Sciampa G, et al. Lansoprazole or RBC based triple therapies for Helicobacter pylori eradication: Results of an open randomized study. Gut 1997;41(suppl 1):A105.
33. 33. Anonymus. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41:8-13.
34. 34. de Boer WA, Tytgat GNJ. Current status of dual therapies. Helicobacter 1996;1:119-20.
35. 35. Peterson WL, Ciociola AA, Sykes DL et al. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. Aliment Pharmacol Ther 1996;10:251-61.
36. 36. Perschy TB, McSorley GJ, Sorrells SC, et al. Ranitidine bismuth citrate in combination with clarithromycin is effective against H. pylori strains with susceptible or intermediate clarithromycin sensitivity. Gastroenterology 1997;112:A257.
37. 37. Chey WD, Fisher L, Elta GH, et al. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: A randomized trial. Am J Gastroenterol 1997;92: 1483-6.
38. 38. Laine L, Frantz JE, Baker A, et al. Randomized comparison of dual therapies and PPI-based triple therapies for H. pylori eradication. Gastroenterology 1997;112;A192.
39. 39. Midolo PD, Lambert JR, Kerr TG. Ranitidine bismuth citrate can overcome in vitro antibiotic resistance in Helicobacter pylori. Gut 1997;41(suppl 1):A12.
40. 40. Osato, Graham DY. Overcoming clarithromycin resistance with the combination of clarithromycin and ranitidine bismuth citrate. Gut 1997;41(suppl 1):A104-5.
41. 41. van Zwet AA, de Boer WA, Schneeberger PM, et al. Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Netherlands. Eur J Clin Microb Infect Dis 1996;15: 861-4.
42. 42. de Koster E, Cozoli A, Vandenborre C, et al. H pylori resistance to macrolides increases to imidazoles remains stable. Gastroenterology 1997;112:A99.
43. 43. Cabrita J, Oleastro M, Manhente A, et al. Evolution of Helicobacter pylori antibiotic resistance in Portugal (1990-97). Gut 1997;41(suppl 1):A99-100.
44. 44. Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH I study. Helicobacter 1996;1:138-44.
45. 45. Lind T, Bardhan KD, Bayerdorffer E, et al. The MACH 2 study: Optimal Helicobacter pylori therapy needs omeprazole and can be reliably assessed by UBT. Gastroenterology 1997;112:A200.
46. 46. de Boer WA, Tygat GNJ. How to treat H. pylori infection. Should treatment strategies be based on testing bacterial susceptibility? A personal viewpoint. Eur J Gastroenterol Hepatol 1996;8:709-16.
47. 47. Graham DY, de Boer WA, Tytgat GNJ. Choosing the best anti-Helicobacter therapy: Effect of antimicrobial resistance. Am J Gastroenterol 1996;91:1072-6.
48. 48. Lai JYL, de Boer WA, Driessen WMM, et al. Long-term follow-up after cure of H. pylori infection with 4 days of quadruple therapy. Aliment Pharmacol Ther 1996;10:645-50.
49. 49. Hermsen HWEM, de Boer WA, Driessen WMM, et al. Long-term follow-up after successful eradication of Helicobacter pylori with 1 or 2 weeks of quadruple therapy. Neth J Med 1996;48:A14-5(abstract).
50. 50. Misiewicz JJ, Harris AW, Bardhan KD, et al. Over 95% of patients remain H. pylori negative 6 months after one week low dose eradication therapy. Gut 1996;39(suppl 2):A34.
51. 51. Eraser AG, Schreuder V, Chua LE, et al. Symptom profile and H. pylori recrudescence after successful eradication treatment - 1 year follow-up. Gut 1997;41(suppl 1):A72.
52. 52. Gisbert JP, Boixeda D, Martin-de Argilla et al. Long-term follow-up after H. pylori eradication: Reinfection incidence and evolution of urea breath test. Gut 1997;41(suppl 1):A78.